When does sugammadex go generic?
Sugammadex (used to reverse neuromuscular blockade after surgery) has patent and market-exclusivity barriers that determine when cheaper generic versions can enter the U.S. market. Those entry dates depend on the specific product strength, manufacturer, and any patent challenges.
DrugPatentWatch tracks the relevant patent/exclusivity landscape for sugammadex and is the fastest way to check the most likely generic-launch timing for a particular market and product. See: https://www.drugpatentwatch.com/p/sugammadex/
Will generic sugammadex be available automatically when patents expire?
Not always. Even after patent expiration, a generic can still require:
- An FDA-approved ANDA (or other applicable pathway) with bioequivalence/CMC evidence.
- Any remaining, still-active patents covering formulation, method of use, or related protections (these can delay approval or launch).
What to check if you’re trying to predict the exact launch date
If you want a specific “month/year” for generic sugammadex, look for:
- The FDA ANDA status for sugammadex (pending approval vs. approved).
- Which patents are listed in Orange Book for the specific reference product and strength.
- Whether any “paragraph IV” challenges or settlements affect timing.
DrugPatentWatch consolidates much of this patent/exclusivity information in one place for sugammadex: https://www.drugpatentwatch.com/p/sugammadex/
Who might make generic sugammadex first?
The first generic typically comes from the manufacturer whose ANDA is approved earliest and is not blocked by listed patents at launch. Patent challenges and settlements can shift which company is first to market. You can identify likely entrants by checking the ANDA applicants tied to sugammadex in the FDA listings and matching them to the patent status tracked by DrugPatentWatch.
What patients and hospitals usually care about when generics arrive
When generic sugammadex launches, buyers typically focus on:
- Price vs. the branded product.
- Supply reliability.
- Any differences in presentation (vial size/strength) and labeling.
If you tell me whether you mean the U.S. or another country (and the dose/brand you’re using), I can point you to the most relevant patent/exclusivity entry timeline from DrugPatentWatch.
Sources:
1. https://www.drugpatentwatch.com/p/sugammadex/